Inetetamab, a novel mAb binding to the HER2 receptor ECD subdomain IV, is currently only available in China and has been approved in combination with vinorelbine for HER2-positive breast cancer patients who have undergone chemotherapy by China National Medical Products Administration (NMPA) in July 2020. This evidence concerns the gene ERBB2 and breast carcinoma.